Valby, Denmark, 27 October 2025 - H. Lundbeck A/S (Lundbeck) today announced a strategic collaboration with OpenAI to transform how the company innovates and operates across its entire value chain - from molecule to patient. Through the deployment of ChatGPT Enterprise to its global workforce, Lundbeck empowers employees with AI capabilities designed to accelerate discovery, enhance decision-making, and drive unprecedented efficiency. The collaboration marks a bold step toward redefining innovation in brain health.

Brain disorders such as migraine, depression, and anxiety affect nearly half of the global population, leaving millions with unmet medical needs. By integrating OpenAI's advanced AI tools into daily workflows, Lundbeck aims to free individuals and teams from repetitive tasks, allowing more time for creativity and breakthrough thinking in the pursuit of transformative treatments.

The collaboration combines Lundbeck's deep scientific expertise with OpenAI's pioneering technology and expert resources. Together, they will explore AI-driven use cases across research, development, and commercial functions, always guided by robust ethical, compliance, and data governance frameworks.

Following a successful pilot, Lundbeck has already seen how ChatGPT accelerates research, streamlines analysis, and boosts quality across functions. Expanding this focus on AI capabilities will for instance enable scientists, clinicians, and commercial teams to work with greater speed and creativity.

Claus Thomsen, SVP, Global IT at Lundbeck comments: "This collaboration is about giving our people new ways to generate insight and deliver impact. By integrating AI into our daily processes, we're unlocking new levels of efficiency and innovation, bringing science and technology together to improve outcomes for people living with brain disorders."

"Lundbeck's adoption of ChatGPT Enterprise highlights the growing role of AI in advancing science responsibly," said Orian English, EMEA go-to-market leader at OpenAI. "By integrating AI into daily workflows, Lundbeck teams can work smarter, faster and with greater focus to pursue new frontiers in brain research."

Lundbeck has previously announced strategic partnerships with the Danish Centre for AI Innovation - focused on leveraging the Gefion AI supercomputer - and Iambic Therapeutics to advance the use of AI in drug discovery.

Contacts

About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.